GTx director named interim CEO of London company

Memphis Business Journal
September 18, 2007

Rosemary Mazanet, an independent director at GTx Inc., has been named interim CEO of Morria Biopharmaceuticals PLC, a London-based private drug company.

"I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation," Mazanet said in a statement. "We believe this new family of Multifunctional Anti-Inflammatory Drugs could bring significant benefits to patients with many different inflammatory conditions including skin, respiratory and gastrointestinal indications."

Mazanet serves on the board of many private and public pharmaceutical companies. From June 1998 to February 2004, Mazanet served as chief scientific officer and a general partner of Oracle Partners LP, a health care investment firm. She also serves on the board of Memphis-based GTx (NASDAQ: GTXI).

GTx is a biopharmaceutical company that seeks to discover, develop and commercialize small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions.